Press release
Merck & Co. Ordered to Pay Attorneys’ Fees, Costs Following VIOXX® Consumer Fraud Finding
ATLANTIC CITY, N.J. – New Jersey Superior Court judge Carol E. Higbee has ordered pharmaceutical giant Merck & Co. to pay fees and costs to a group of attorneys who proved in court that Merck committed fraud by deceiving doctors about the cardiovascular risks of the popular painkiller VIOXX® and deliberately hiding information about those risks from physicians.Merck could have settled both consumer fraud claims for less than $5,000, but fought the allegations in an April 2006 trial. Similar consumer fraud claims are pending in thousands of additional cases against Merck.
Following the trial, jurors awarded $13.5 million in compensatory and punitive damages to 77-year-old John McDarby, who suffered a heart attack after taking VIOXX® for four years. Jurors also agreed that Merck committed consumer fraud and awarded an additional $4,013.36 to Mr. McDarby and $45 to second victim Thomas Cona based on the cost of their prescriptions.
The order signed June 15 awards approximately $4 million in fees and costs for the attorneys who represented Mr. McDarby and Mr. Cona.
“It is a pity that Merck is forcing our nation’s court system to waste thousands of hours of time and millions of dollars to hear these fraud claims after a jury has already said the company committed fraud,” says lead attorney Mark Lanier of The Lanier Law Firm. “This is lawsuit abuse by Merck, plain and simple.”
The New Jersey Consumer Fraud Act provides for “reasonable attorneys’ fees, filing fees and reasonable costs of suit” to plaintiffs who prove a consumer fraud claim. The New Jersey statute does not limit counsel fees according to the amount of the original claim. According to the court, the law “provides an incentive to competent counsel to undertake high-risk cases and to represent victims of fraud who suffer relatively minor losses.”
The ruling notes that Merck spent $500 million defending Vioxx cases in 2006, and the company has reserved more than $850 million to defend future cases.
Prior to the ruling, Merck withdrew any objection to the amount of time expended by attorneys for the plaintiffs or the hourly rate charged by plaintiffs’ counsel. The company acknowledged in a court filing that Merck’s overall fees and costs “were at least as high as plaintiffs corresponding fees and costs.”
With offices in Houston and New York, The Lanier Law Firm is committed to addressing client concerns with effective and innovative solutions. The firm is composed of outstanding trial attorneys with decades of experience handling cases involving pharmaceutical liability, asbestos exposure, business fraud, serious personal injuries, product liability, and toxic exposure.
The Lanier Law Firm
www.lanierlawfirm.com
Houston Law Office
6810 FM 1960 West
Houston, Texas 77069
(713) 659-5200
(713) 659-2204 – Fax
New York Law Office
Lanier Law Firm, PLLC
Tower 56
126 East 56th Street, 6th Floor
New York, NY 10022
(212) 421-2800
(212) 421-2878 – Fax
Press contact:
Alan Bentrup
800-559-4534
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Merck & Co. Ordered to Pay Attorneys’ Fees, Costs Following VIOXX® Consumer Fraud Finding here
News-ID: 22495 • Views: …
More Releases for Merck
Swine Fever Vaccine Market Detailed in New Research Report By 2032 | Merck & Co. …
🚀 𝐒𝐰𝐢𝐧𝐞 𝐅𝐞𝐯𝐞𝐫 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐭𝐨 𝐠𝐫𝐨𝐰 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟓.𝟗% (𝟐𝟎𝟐𝟓 - 𝟐𝟎𝟑𝟐)
The Swine Fever Vaccine Market Report is the result of extensive research and analysis conducted by our team of experienced market researchers through -
» 70% efforts of Primary Research
» 15% efforts of Secondary Research
» 15% efforts from the subscription to Paid database providing industry overview, macro and micro economics factors, and financials of private limited companies
📈…
Women's Health Market Industry Growth Report to 2031 Merck KGaA, Merck & Co, Fer …
[New York, December 2024] Women's Health encompasses a broad spectrum of medical and wellness services tailored to address the unique health needs of women across all life stages. This crucial sub-market of healthcare highlights the necessity for specialized treatments, preventive care, and holistic wellness approaches that resonate with today's female patients. Women's Health isn't just a niche sector; it represents a burgeoning field within healthcare, mirrored by an increasing global…
Laboratory Syringe Market Size, Growing Demand to 2036 GESERCO, Merck Millipore, …
A laboratory syringe is a precise instrument commonly used for the accurate measurement and transfer of liquids or gases in scientific experiments. Unlike standard medical syringes, laboratory syringes are often made of materials such as glass or high-quality plastic to withstand chemical reactions and offer greater clarity for observing contents. They come in a range of sizes, from as small as 1 mL to over 100 mL, and are often…
Leuprorelin Acetate Market Analysis By Top Keyplayers - Merck, Takeda, MediGene, …
The "Leuprorelin Acetate Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Leuprorelin Acetate Market, 2024-2031
Verified Market Research's most recent report, "Leuprorelin Acetate Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides an in-depth…
Avelumab Market Analysis By Top Key Players - Merck, Pfizer, Merck
The "Avelumab Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Avelumab Market, 2024-2031
Verified Market Research's most recent report, "Avelumab Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2030," provides an in-depth examination of the…
Nanobodies Market to See Booming Growth 2021-2028 | Novo Nordisk A/S, Merck & Co …
𝐍𝐚𝐧𝐨𝐛𝐨𝐝𝐢𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 top level players are analyzed in report based on current and future development status, and Nanobodies market estimations from 2021 to 2028 in terms of revenue and volume. This report provides strategic recommendations consulted by the industrial experts including market share worldwide, future outlook, cost profit structure, supply, raw materials, labour cost, manufacturing expenses, latest market trends, demands, ROI.
The Nanobodies market report analyse the manufacturing cost of the…